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Dear Editor,
Type 1 diabetes mellitus (T1D) is an autoimmune disease
characterized by the infiltration of inflammatory cells into the
pancreatic islets of Langerhans, followed by the selective
destruction of insulin-producing β-cells, resulting in
hyperglycemia. One of the mechanisms causing β-cell death
is the intra-islet release of inflammatory mediators such
as interleukin-1β (IL-1β), tumor necrosis factor (TNF)
and interferon-γ (IFN-γ) by activated immune cells.1 Hence,
the transcription factor NF-κB promotes pro-inflammatory
and pro-apoptotic responses in β-cells on cytokine exposure.
A transgenic mouse line in which NF-κB activation is
attenuated specifically in β-cells conferred nearly complete
protection against multiple low dose streptozotocin
(MLDSTZ)-induced T1D.2 Contrary, mice with constitutively
active NF-κB signaling in β-cells spontaneously develop
full-blown immune-mediated diabetes.3
The ubiquitin-editing enzyme A20 is a critical negative
regulator of NF-κB signaling in response to multiple stimuli,
including TNF and IL-1. Moreover, A20 can also act as a
strong anti-apoptotic protein in specific cell types.4 A20 has
been identified as the most highly upregulated anti-apoptotic
protein in cytokine-stimulated primary islets and insulinoma
cell lines.5 Consistent with this, overexpression of A20 in
islets confers resistance to cytokine-mediated activation of
NF-κB, protecting them from apoptosis in the early post-
transplantation period.6 Interestingly, not only have NF-κB
polymorphisms been identified in patients with T1D,7 also
A20/TNFAIP3 has been identified as a T1D susceptibility
locus in humans.8 Together, these data suggest an important
role for A20 in β-cell function and T1D. Therefore, we
generated and characterized A20-deficient mice which lack
expression of A20 specifically in β-cells (Supplementary
Figure 1A).
We first confirmed the anti-apoptotic function of A20 in
β-cells, as primary islets isolated from β-cell-specific
A20 knockout (A20β−KO) mice were more susceptible
to cytokine-induced cell death compared with wild-type
islets (Supplementary Figure 1A). As A20 has a crucial role in
β-cell survival in vitro, we next investigated whether
A20β-KO mice would be more susceptible to diabetes
development when compared with wild-type littermates.
A20β-KO mice aged normally without any evidence of
metabolic defects. Phenotypic analysis of A20β-KO mice up
to the age of 12 months revealed no pathological signs
in the pancreas. A20β-KO mice and control littermates
were subjected to a model of T1D induced by MLDSTZ,
however, both control and A20β-KO mice developed a
similar hyperglycemia, which was confirmed in a glucose
tolerance test (ipGTT) performed 5 weeks after the first STZ
injection (Supplementary Figure 1B). Next, we crossed
A20β-KO mice with C57BL6-Ins2Akita/J mice, which carry a
mutation in the insulin Ins2 gene that prevents normal folding
and secretion and induces endoplasmic reticulum stress
leading to β-cell death. Mice carrying the Ins2Akita mutation
become hyperglycemic very early in life, however, no
differences could be observed in conditions of A20 deficiency
in β cells. In agreement, ipGTT shows severe and similar
defects in insulin secretion in both Ins2Akita and A20β−KO/Akita
mice (Supplementary Figure 1C). Finally, A20β-KO mice
were backcrossed into a non-obese diabetic genetic
background, and glucose levels were measured every
week in order to follow diabetes development. Although
only 40% of all mice developed diabetes, no differences
could be detected between control and A20β-KO mice
(Supplementary Figure 1D). In conclusion, A20 deficiency
in β cells does not affect β-cell apoptosis nor disease
development in vivo.
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